Colispas is an analgesic and antispasmodic combination therapy generally used for symptomatic relief when symptoms related to physical discomfort are dominated by acute, internal muscle contractions. It is applied across domains where short-term symptomatic assistance is appropriate for heightened patient distress.

Management of Severe Menstrual Cramps (Dysmenorrhea)

This medication is commonly used to address the severe and disruptive symptoms associated with primary dysmenorrhea. The NSAID component is intended for the management of primary dysmenorrhea. The combination may assist in managing symptom intensity and contributes to easing distress associated with the severe cramping and spasm. This generally supports the patient during difficult episodes by easing discomfort during periods of cyclical symptoms.

The medication is commonly used to help with conditions characterized by acute episodes, such as: primary dysmenorrhea, intestinal colic, and acute abdominal cramping.

Relief from Acute Colicky and Abdominal Pain

Colispas is applied in contexts where pronounced symptoms of colicky pain or sudden abdominal cramping are present. This includes painful episodes arising from smooth muscle contractions in the intestines. The inclusion of an antispasmodic agent supports general well-being during symptomatic phases and provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.

---

Quick Fact: Used for Managing Acute Spasmodic Discomfort

Official Eligibility and Contraindications

The eligibility profile for Colispas (Dicycloverine/Mefenamic Acid) is based on the strictest regulatory rules for each active component, as defined by governmental authorities.

Category	Official Regulatory Status
Age Restriction	Contraindicated in infants under 6 months of age. Safety and effectiveness are not established in children below 14 years of age. Older adults require caution due to increased risk.
Pregnancy/Lactation	Contraindicated during the third trimester of pregnancy. It is also contraindicated in nursing mothers.
Absolute Contraindications	Prohibited for patients with a history of NSAID allergy, active gastrointestinal ulceration or bleeding, severe renal failure, or severe heart failure (NYHA II-IV).
Condition-Specific Bars	Use is strictly prohibited in patients with glaucoma, obstructive uropathy, obstructive gastrointestinal disease, severe ulcerative colitis, or myasthenia gravis.

Use is contraindicated for managing pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Use requires caution in patients with non-severe hepatic or renal impairment or hypertension.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Colispas (Dicycloverine and Mefenamic acid), strictly based on government regulatory information.

---

Documented Interaction Restrictions

Restriction Category	Interacting Substances/Agents
Formal Contraindications	Antiglaucoma Agents and Other Systemic Non-Aspirin NSAIDs (including COX-2 inhibitors).
Increased Bleeding Risk	Oral Anticoagulants, Antiplatelet Agents, and Selective Serotonin Reuptake Inhibitors (SSRIs).

---

Pharmacodynamic and Pharmacokinetic Effects

The NSAID component, Mefenamic acid, is documented to interact with several classes of medicines. It may reduce the efficacy of Diuretics and ACE Inhibitors/ARBs, and it officially reduces the renal clearance of Lithium and Methotrexate, leading to elevated plasma concentrations of those drugs. Furthermore, co-administration with Alcohol is noted to increase the risk of gastrointestinal bleeding.

The antispasmodic component, Dicycloverine, may potentiate the effects of Other Drugs with Anticholinergic Activity and may antagonize the effects of other Gastrointestinal Motility Drugs. Co-administration with Antacids (specifically Magnesium Hydroxide) is officially noted to interfere with Dicycloverine absorption and significantly increase the absorption rate of Mefenamic acid, creating a timing constraint that states simultaneous use should be avoided. The risk of serious gastrointestinal complications due to the NSAID component is officially noted to be increased in the elderly population.

Colispas functions as a smooth muscle relaxant by targeting specific ionic and signaling pathways within the visceral muscles of the gastrointestinal tract. The primary mechanism involves modulation of calcium ion flux necessary for smooth muscle cell activation. Specifically, Colispas acts to inhibit voltage-dependent calcium channels (VDCCs) on the smooth muscle cell membrane, resulting in a measurable reduction of the intracellular calcium concentration available to initiate the contraction cascade.

This reduction in available intracellular calcium interferes directly with the activation of myosin light-chain kinase (MLCK). MLCK is the enzyme responsible for phosphorylating the myosin light chains, a biochemical requirement for initiating the actin-myosin cross-bridge cycle and subsequent muscle fiber shortening. By indirectly decreasing MLCK activity, Colispas prevents the sustained, non-adrenergic, non-cholinergic contraction of the smooth muscle fibers.

The resulting system-level physiological consequence is a direct decrease in the amplitude and frequency of peristaltic contractions throughout the gut wall. This mechanism specifically modulates gut motility by promoting a more regulated and less spastic rhythm of muscle activity, primarily focusing on the smooth muscle layer of the large intestine and colon.

How to Use Colispas: Administration Guidelines

This section describes the high-level principles for using the fixed-dose combination of Dicycloverine hydrochloride and Mefenamic acid, known by the brand name Colispas.

---

Administration and Dosage Regimen

The medicine is designed for oral administration, available as a tablet or oral suspension. The dosing regimen is structured for short-term management of acute symptoms.

• Initial Dose: The Mefenamic acid component is typically initiated at a dose of 500 mg orally, administered once.
• Maintenance Dose: Following the initial dose, the maintenance dose for the Mefenamic acid component is 250 mg administered every six hours (q6h) as needed.

---

Administration Conditions and Duration

General principles apply to the proper use of this combination therapy, particularly concerning the intake of the Mefenamic acid component, which is a Nonsteroidal Anti-inflammatory Drug (NSAID).

Usage Constraint	General Guidelines
Intake with Food	The medicine is taken with or immediately after food or milk to minimize the potential for gastrointestinal discomfort.
Physical Handling	Tablets are to be swallowed whole and are not to be crushed, broken, or chewed.
Duration Limit	Treatment is generally limited to the shortest duration necessary, typically not exceeding two to three days for primary dysmenorrhea and a maximum of seven days for other acute conditions.

---

Procedural and Population Rules

Use of the adult-strength formulation is generally restricted by age, as it is not recommended for use in children under 12 to 14 years of age. In the event a dose is missed, it is usually skipped if the next scheduled dose is nearly due; it is standard practice never to take a double dose to compensate.

Evidence for Management of Severe Menstrual Cramps

Research for the fixed combination of Dicycloverine and Mefenamic Acid has been conducted using Randomized Controlled Trials (RCTs) and controlled comparative studies assessing short-term, episodic symptom patterns related to menstrual pain. These trials primarily monitored outcomes describing perceived discomfort, such as changes in pain intensity quantified by standardized scales. Research highlights changes measured during the study period, showing that in observed adult populations with moderate to severe primary dysmenorrhea, the combination product was associated with patterns in measured symptom changes when compared to other observed groups. Evidence focuses on temporary, short-term observations across one or a few menstrual cycles, and comparative evidence against all other NSAID-spasmolytic combinations is limited.

---

Evidence for Relief from Acute Colicky and Abdominal Pain

The combination was evaluated in patients presenting with conditions characterized by fluctuating or episodic manifestations, such as acute abdominal pain or intestinal colic. Research explored study designs combining an antispasmodic agent with an analgesic for this type of acute pain. These studies monitored outcomes describing episodic changes, with measurements often taken within the first hours of administration. Findings indicate patterns related to temporary changes in measured symptoms. The data show patterns related to the concept of combining active components, but the available evidence quality varies when comparing it specifically to all single-drug options or all alternative combination therapies for colic.

---

Long-Term Evidence and Research Gaps

Studies conducted during periods of increased symptom activity primarily involve follow-up durations that were limited to the acute phase of symptoms (e.g., one to two menstrual cycles or a few hours for colic). Consequently, the existing evidence base mainly contributes to understanding short-term symptom patterns. Long-term outcomes beyond these acute phases are not fully established, and limited information exists regarding the effect of repeated, episodic use over a sustained period of time.

The primary clinical research has focused on a narrow population (non-pregnant adults). Data for certain groups, such as adolescents or older adults presenting with these acute conditions, remain insufficient. Evidence quality varies across studies, and research does not provide personal predictions regarding whether an individual in these less-studied groups will respond similarly.

Key Studies & References

1. Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review

Common questions about Colispas (FAQ)

---

Q: Does Colispas treat gas and bloating, or only the pain from muscle spasms?

Official information states that the dicyclomine component works to relax the smooth muscles of the bowel to reduce cramping and spasm pain. The mefenamic acid component is indicated for relieving pain, including abdominal pain.

However, certain labels for the mefenamic acid component list symptoms such as excess air or gas in the stomach or intestines as potential side effects.

---

Q: Is Colispas considered a primary treatment for Irritable Bowel Syndrome (IBS) symptoms?

The dicyclomine component, which is one of the two active ingredients, is officially indicated in regulatory documents for the treatment of Irritable Bowel Syndrome (IBS).

The fixed-dose combination product, Colispas, is generally indicated for the short-term relief of acute pain associated with muscle spasms and dysmenorrhea (menstrual pain).

---

Q: Is Colispas similar to over-the-counter pain medications?

Colispas is a prescription medicine containing two active ingredients: an antispasmodic (dicyclomine) and a Nonsteroidal Anti-inflammatory Drug (NSAID) called mefenamic acid. While the mefenamic acid component is chemically similar to some common NSAID pain relievers, the addition of the antispasmodic provides a dual-action approach for pain where muscle spasm is a factor.

---

Q: Do the side effects of Colispas last for a long period of time?

Regulatory information for the dicyclomine component indicates that if mild side effects occur, they may go away within a few days or a couple of weeks, or they can also persist.

The mefenamic acid component has a relatively short elimination half-life of approximately two hours, which is a clinical measurement of how the drug is processed.

---

Q: How long does it usually take for Colispas to start working after it is taken?

Official prescribing information indicates that the mefenamic acid component is rapidly absorbed after being taken orally. Regulatory information indicates the mefenamic acid component typically reaches its highest measured concentration in the blood plasma after one to four hours.

---

Q: How does the mefenamic acid component in some Colispas formulations work?

Mefenamic acid is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its mechanism of action involves stopping the production of chemical messengers called prostaglandins that cause pain and inflammation by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes.

---

Q: What is the shelf life of Colispas, or how should it be stored?

The product should be stored in the manner described on the specific product label or packaging. In alignment with general guidelines for all prescription medications, official documents state it should be kept securely locked or out of sight and reach of children and stored according to the specified temperature and conditions.

---

Q: Is an increase in heart rate a possible side effect of Colispas?

Official safety information for the dicyclomine component notes that it may cause an abnormal or rapid heart rate (medically known as tachycardia).

Regulatory information notes that caution is required for patients with existing heart conditions.

---

Q: Does taking Colispas with corticosteroids increase any safety risks?

Regulatory safety information for the mefenamic acid component (NSAID) includes a warning about concomitant use with oral corticosteroids.

This combination significantly increases the risk of serious gastrointestinal bleeding and ulceration.

---

Q: What is the expected duration of effect for a single dose of Colispas?

The mefenamic acid component has an elimination half-life of approximately two hours, a clinical measurement of how the drug is processed.

The dicyclomine component's typical dosing regimen is set at four times daily (every six hours).

---

Q: Is Colispas an appropriate choice for individuals with asthma?

According to official regulatory information, the mefenamic acid component is contraindicated in individuals who have a history of aspirin-sensitive asthma.

This is because the medication may cause a severe reaction or worsen the condition.

---

Q: Can Colispas cause confusion or changes in mood?

Safety warnings for the dicyclomine component address potential effects on the central nervous system. These warnings note that the medicine may cause effects such as confusion, hallucinations, irritation, and sudden or unusual mood or behavior changes.

---

How to Store and Dispose of Colispas? — Official Regulatory Information

No specific, publicly available official drug label or regulatory document detailing the mandatory storage, handling, and disposal instructions for a product named Colispas was found across major governmental health agencies (e.g., FDA, EMA, Health Canada, TGA, NIH).

In the absence of a specific official label, storage and disposal must adhere to general regulatory guidelines for prescription medicines.

Storage & Disposal Scope	Official Labeled Requirements
Labeled storage temperature requirements	Data not found in authorized government sources.
Light/moisture protection requirements	Data not found in authorized government sources.
Disposal instructions (as documented)	No specific instructions found; follow standard federal, state, and local disposal laws for pharmaceuticals.
Child-protection storage requirements	Keep all medicines, including this product, securely locked or out of sight and reach of children.

All medicines should be stored according to the temperature and conditions stated on their packaging label to maintain identity, strength, quality, and purity. Disposal of unused or expired pharmaceuticals should follow recommended community drug take-back programs or general non-flush disposal rules, as advised by agencies like the FDA.